Redx Pharma has been granted a patent for novel compounds and pharmaceutical compositions that act as modulators of Rho-associated protein kinase (ROCK), specifically ROCK1 and/or ROCK2 inhibitors. These compounds are useful in treating ROCK mediated diseases. GlobalData’s report on Redx Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Redx Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Redx Pharma's grant share as of January 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11878020B2) discloses a compound of formula (I) and its pharmaceutically acceptable salts. The compound includes various specific structural features, such as A1 being selected from C—H, C—F, C—Cl, and other groups, A2 being C—H or C—F, and A3 being C—H. Additionally, the compound may have R8 as H or Me, and R6 as H. The compound can be represented by formula (Ia) and may have B as a 6-membered carbocyclic ring or a 10-membered heterocyclic fused bicyclic ring system, among other options.
Furthermore, the patent claims cover various aspects of the compound, including the selection of L1 and L2 from specific groups, as well as the independent selection of RA, RB, RC, and RD from certain groups. The compound may have R2 as H, CN, methyl, or other specified groups, while R4 can be F, Cl, methyl, or other defined options. Moreover, R5 is specified as either H or methyl. The patent also includes claims related to a pharmaceutical composition comprising the disclosed compound and a pharmaceutically acceptable excipient, with the possibility of including an additional pharmaceutically active agent in the composition. Overall, the patent provides detailed information on the compound's structure and its potential pharmaceutical applications, emphasizing the specific features and variations covered by the granted claims.
To know more about GlobalData’s detailed insights on Redx Pharma, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
